Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see interest in Positron.
The value is much higher.
Betting on the stock gaining more interest as the imaging industry speeds towards PET.
Watching closely.
March 24, 2020
Dear Positron Shareholders,
On behalf of our investors and supporters we are pleased to offer some forward guidance to our business.
The cardiac PET industry is healthy and in the best position we have seen in a decade. A great deal of the industry’s vision and best practices come from the leadership of the societies and coalitions within the industry fighting to solidify reimbursement and the advocacy of this superior cardiac diagnostic technology. We are confident there will be continued support and advancements the modality. Additionally we are encouraged by the supply of radiopharmaceuticals, new and improved coronary flow reserve software complementing our Attrius® PET scanner and an overall evolution underway from SPECT to PET, which all play an important role in the increase in demand for PET. Positron is well positioned to deliver systems from inventory and through its joint venture partner Neusoft Medical.
Over the past year we have increased revenues generated from annual clinical and technical services agreements while also improving margins. We are pleased with our sales pipeline which we expect to report new developments in the near future.
As a company we continue to maintain our focus on our systems, services and facilitating customer’s needs towards successful cardiac PET programs. We are in the process of divesting of all SPECT assets as well as perfecting value and income from royalty agreements; all with the intent of improving our balance sheet with capital that will be applied to expanding operations and customer acquisitions.
Positron is also committed to meeting the requirements of a public company. We are exploring the timing to return to a fully reporting company and will begin enacting corporate governance required. We believe this is a key component for growth and investor confidence.
In recent years there have been a number of hurdles that both Positron and the cardiac PET industry have overcome; all of which only made us stronger and in the best position to lead this industry with our PET technology and services. Positron offers the best in PET through quality, services, price and the only dedicated PET system in the world.
In coming months it is our plan to report our progress on PET system sales, industry growth, capital and income from non-PET properties, additional personnel and initiatives on expansion and the return to a fully reporting public company.
As always thank you for your support of Positron. We will update any and all material developments in real time. Best Regards,
Adel Abdullah Positron Corporation President
Someone must understand there is a hidden gem here. Nice to see a new found interest in Positron.
We are patiently watching for a glimmer of guidance.
Cardiology on the front line.
“Heart conditions accentuated in coronavirus patients”.
It had a false break-out to 1 dollar about 3 Months ago. I dont think technicals are very valuable here. Its either worth a lot or nothing. Pure gamble here. I invested for the Star Trek positron "IMPULSE" engine capable of 20%^ of Light speed. The medical scanner business is a bonus.
Correct.
$600,000 per scanner is a fair price for an average size clinic. This $1.5 million mentioned can only be a lower end PET/CT.
Once the country “opens” and non C19 healthcare resumes the company should be in position to expand its installation base.
Healthcare will be the top industry for years to come. Spending on advanced medicine that differentiates practices will be the new norm.
Nice to see that the stock trading. Worth watching closely for a breakout.
Positron has been dark to the market since recovering from bankruptcy. Dark companies can trade at significant discounts because there is no clarity of their financial position. This is the risk we are taking here, but it also offers potential significant upside.
The point of me positing that article was to show the demand for PET-only scanners, Positron's new PET only Atrius system sells for $400 - $600k depending what options are selected.
Reviewing industry information leads me to believe Positron is still a respected competitor in the cardiac PET business, possibly even a market leader who developed the most widely used cardiac PET software.
Yes its interesting but the whole company is only worth about 3 Mill dollars and the cost of each Pet Scanner is about 1.5 Mill dollars. This suggests that the market does not accord a great deal of probability to the idea that sales will be made? Maybe they can sell themselves or their technology to Abbots Laboratory who make the 15 Min covid-19 Test?
This article explains the opportunity Positron has ahead it. Positron is the only one making those PET-only systems they say providers are looking for:
https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/making-case-cardiac-pet-buying-evaluate-clinical-business
Positron’s scanner is best utilized for cardiac imaging.
“Lung damage” would be considered too specialized and more observational verses molecular.
Can Pet Scanners be used instead of CT scanners to show Lung damage?
Nice to see a true market forming here.
I would expect money to come into healthcare for the foreseeable future. Safest and most impactful especially in these times.
Let’s see where this goes.
One hundred and fifty billion dollars put aside in the stimulus bill for medical equipment = that would buy a few PET scanners I guess?
I sort of see that as a kind of warning to the shorters who are keeping this stock artificially down that they had better cover or be forced to scramble to buy at several dollars in a year's time?
For all who follow Positron Corporation:
Today Positron put out a Letter to Shareholders on their website
www.positron.com
GOOD LUCK TO ALL !!!
This is true.
Economics may play the most important role in that capacity.
I agree the PET scan can be used for lung scans at greater detail then conventional X rays to detect lesions left by the Corronavirus.
Healthcare will be the one industry that benefits from a new normal.
All healthcare companies worth 10x.
Interesting someone is buying at the ask here. eom.
PET volume growing at steady pace.
https://www.auntminnie.com/index.aspx?sec=log&itemID=128391
I see I googled Positron Dynamics which comes up with the Blurb about the positron rocket taking us to Pluto in a few months and Alpha Centuri in 40 years. I can see though, thanks to your input, that there is another potential quiver in this bow; namely the PET scanner. Interesting
Dark stocks are difficult to research, if you can't even find the company's actual website, or recent news, you probably aren't cut out for investing in dark companies.
Here is a link to their news in 2018 that they made a sale of a PET scanner:
http://www.positron.com/updates/post/positron-announces-sale-of-attrius-pet-scanner
A deeper look into market news shows that the company is alive and well, but they are not up to date with SEC filings, and have gone dark on the news wires until they get caught-up.
If you were capable of researching the market for cardiac PET, you would see cardiac PET testing is gaining traction and is expected to take market share from SPECT in the coming years.
There is nothing in the article that suggests Positrons involvement further the website of Positron dynamics and the ceo (test pilot) suggests only that they are trying to get a CUBESAT built and launched as the next phase of their positron engine for space travel. The medical scanner business is very old and not relevant IMOP
taxibabe, it seems you overthought this and missed he obvious right in front of you.
Follow some of the links posted here recently and see that coronary PET scans are being validated as providing more useful information with less radiation exposure than the current industry standard, SPECT imaging. This company has been at the forefront of developing the software with leading researchers, including Lance Gould, MD at the University of Texas:
https://www.uth.tmc.edu/pet/about-dr-gould.htm
I thought POSC was purely based around the idea of an INTERSTELLAR engine, going about 20% of light. I assumed the idea of the medical scanner was a long defunct notion dating back to 2013.?
Well said.
I have also heard from few sources that reimbursement for PET is now being priced out properly to include all costs associated with cardiac imaging. Seems as though the reimbursement may increase.
The St Joe statement is news to me. I know first hand that the used systems market is done. Only option is new systems. Positron is sole provider of PET only. CT is overrated to unnecessary for cardiac studies.
What industry news are you referring to?
Are you referring to this Diagnostic and Interventional Cardiology article discussing the increasing interest in developing cardiac PET centers:
https://www.dicardiology.com/article/how-start-cardiac-pet-ct-imaging-program
I also see this news that PSU/St. Joseph's bought a cardiac PET scanner that makes no mention of CT, so I have to wonder of that's actually one of Positron's machines, since I think they are still the only manufacturer offering PET-only scanners w/o CT:
https://news.psu.edu/story/606710/2020/02/04/impact/penn-state-health-st-joseph-spring-ridge-offers-expanded-services
My searches aren't turning up any other recent news of significance, so please provide some more specifics!
P.S.: I picked up the 21,797 shares on 1/29 @ $0.16 to round out my position in my brokerage account.
Industry keeps coming out with good news.
We all need to start accumulating this one.
Most importantly for me will be sales of systems. This tells us the hospitals & practices are confident with PET to add the modality or transition out of SPECT.
IMO Sets up perfect for Positron
There's a lot of tough history here for this company and its shareholders, but the fact the company survived and positioned itself to benefit from the mainstream adoption of cardiac PET over the next couple of years could finally make it all worthwhile for the long suffering shareholders.
I accumulated the bulk of my position during the weakness the stock saw during 2018 tax loss selling under $0.05 and didn't put a single share up for sale during this recent spike to $1 because I believe these could be worth multiples more than $1 in a few years, once Flurpiridaz is approved and gives cardiac PET a clear advantage over SPECT (with it's clinical trial's last patient follow-up expected in August 2020) and good execution by Positron in making the most cost effective scanners for small and medium cardiac practices.
I'll continue to accumulate on any weakness, but hope to see the company begin to catch up with filings and relisting soon, so that we can watch their growth story begin to unfold over the next few years in public filings.
PET was dead in water until now. I Has a chance to be the Next Gen SPECT.
IMO addressing pharma was smart.
No sales of systems or new generators for 4 years pushed us all back a decade. That was the issue.
Love is a strong word. I swallowed Rooney's lies hook line and sinker. Remember the cyclotron bs
If you liked it in the past you should love it now. I think our time will come again soon.
IMO Many on sidelines ready to rejoin.
Well it would be nice if posc could sell a bunch of new scanners. I'm so upside down here i all but have up
I would say some inexperienced investors/traders (perhaps doctors) are making the stock go crazy because they are excited about what is going on in the industry and they want in because they the know the company is well positioned to capitalize on the emerging industry trends.
This article does a nice job of summarizing why the industry trends are going to be creating a favorable playing field for PET scanning in general, and Positron Corp. in particular:
https://www.dicardiology.com/article/6-trends-cardiac-nuclear-imaging-asnc-2019-meeting
"Forget FFR-CT, do PET studies and you may get a better result," Mahmarian said. "I think the future of nuclear imaging is bright."
.....
Beanlands said there also is increasing interest in PET imaging because of its superior image quality, speed of the exam and increasing access to PET radiotracers. New tracers on the horizon also will increase the image quality and flexibility of PET to accommodate exercise stress. He said single photon emission computed tomography (SPECT) has been the standard for cardiac nuclear imaging for decades, but PET offers improved image quality for more precise diagnosis.
.....
Flurpiridaz F-18 PET perfusion agent that offers high quality images and can be used with exercise stress;
Even with the ask at a $1, I didn't put in any sell orders, I do think this has potential to be worth more in a few years as these industry trends play out.
I heard they presented at an industry roundtable weeks ago. Many are fearing the used scanner market is exhausted.
To the best of my knowledge only Positron has new PET scanners. Even better is their scanner works with new software technology that makes it the only choice in cardiac imaging.
IMO Physicians know such facts and are planing their next move.
What is going on with this stock ? The spread is huge and no news . something is going on but I cannot find out what
Nice move today, I expect this may move may eventually be supported with more significant volume, once the company is ready to share their updated financials and outlook.
A little actual buying at the ask the past few days....it's been quite a while since we've seen a motivated buyer sniffing around here!
Hopefully a sign the companing is getting closer to coming out of the dark, or maybe just a new customer who likes the fundamentals behind their own investment in a cardiac PET scanner for their practice and sees the opportunity in our equity as well.
I can wait, I do think 2020 is going to be a breakout year for demand for cardiac PET!
“Demand for PET in 2020 will be highest in history. “
RSNA meetings
This is best thing we’ve heard in years.
Does anyone know who is a seller at .20? Do they have many shares? Strange if traders are that concerned in churning hundreds of dollars.
I also hear the company wants to respect the capitalization.
Once this is done it should be clear path higher especially with reporting.
No debt, sales and profitable are a good combination.
Anyone buying this should also be made aware of the Bankruptcy filing indicating that Class 6 Creditors (Insiders) hold a $1,266,849 convertible note that could be converted at a 45% discount to the market. It's discussed in Section 4.8 of the Exhibits filed with the SEC here:
https://www.bamsec.com/filing/161577418007286/3?cik=844985
That could be some significant dilution from our current low O/S. With the current share price @ $0.14, the 45% discount would price shares @ $0.077, which would amount to 16,542,545 shares being issued (not accounting for any interest on the note).
I've been told the note holders are "friendly" to current shareholders, appreciate the value of tight capital structure, and are not going to look to play manipulative games with the stock price prior to conversion.
All that being said, I still really like this company's potential once Lantheus's Flurpiridaz F-18 imaging agent gets approval, which is expected in about a year, and will probably give PET a distinctive advantage over SPECT for imaging accuracy/price/ and half life (allowing exercise induced stress):
http://www.lantheus.com/pipeline/flurpiridaz-f-18/
The market is too thin to use percentages as the gauge of performance.
With more information and filings this stock should respond well.
Unsure who sells such small amounts at these levels. Assume its firms supporting the market. I think once they represent progress the price with blast through this level and then some.
Why? There's man reasons. The company is dark, there's an extremely thin market for their shares, such that the spread is at 0.062/0.15, which is more than a 100% difference.
I picked up some shares last year around this time as they were being thrown out for tax losses @$0.05 and under.
I think cardiac PET is better than SPECT and the company announced last year they had made some sales, which caught my attention. I called the company and asked if they were tow seperate sales, as they curiously released the same generic PR on different dates (9/6/2018 to their website and 10/2/2018 to the newswire), their President told me that had made multiple sales in the past year after not making any since 2013, that there was a watershed moment in cardiac PET happening with newer studies and the scarcity of Tc-99 for SPECT at the time.
POSC why down 30%?
End of tariffs
Good news continues
Great news, thanks for the update!
Looks like SNMMI worked diligently with ACC, ASNC, and CAA to keep Cardiac PET MPI reimbursable by CMS at economically reasonable levels:
http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=32960
To be honest, I didn't even know this issue was brewing, but hopefully this assurance or economical reimbursement rates helps Positron get some more sales through their funnel and enables them to come out of the dark with a stronger business case for investors than they've had in the past decade or longer.
Followers
|
165
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
19500
|
Created
|
07/13/03
|
Type
|
Free
|
Moderators |
Symbol: OTC: POSC
Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.
Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source. Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.
Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.
Key Business Components
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology." Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.
Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.
Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011). Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging.
Products
Attrius®
Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.
The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists. This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists. Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.
Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.
Positron is PET.
Company Website: http://www.positron.com
Share Structure
October 2017
Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979 Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |